pci-32765 and Mycoses

pci-32765 has been researched along with Mycoses* in 7 studies

Reviews

2 review(s) available for pci-32765 and Mycoses

ArticleYear
Fungal Infections Potentiated by Biologics.
    Infectious disease clinics of North America, 2020, Volume: 34, Issue:2

    Biologic therapies including monoclonal antibodies, tyrosine kinase inhibitors, and other agents represent a notable expansion in the pharmacotherapy armamentarium in treatment of a variety of diseases. Many of these therapies possess direct or indirect immunosuppressive and immunomodulatory effects, which have been associated with bacterial, viral, and fungal opportunistic infections. Careful screening of baseline risk factors before initiation, targeted preventive measures, and vigilant monitoring while on active biologic therapy mitigate these risks as use of biologics becomes more commonplace. This review compiles reported evidence of fungal infections associated with these agents with a focus on the tumor necrosis factor-α inhibitor class.

    Topics: Adenine; Antigens, CD; Biological Products; Clinical Trials as Topic; Humans; Mycoses; Piperidines; Tumor Necrosis Factor-alpha

2020
Non-Aspergillus invasive mould infections in patients treated with ibrutinib.
    Mycoses, 2020, Volume: 63, Issue:8

    Invasive mould infections (IMIs) are very rare in patients with lymphoid malignancies. However, IMIs, mostly due to Aspergillus species, have been increasingly reported in such patients receiving ibrutinib (IBR). There is paucity of information regarding non-Aspergillus invasive mould infections (NAIMIs) in this setting, OBJECTIVES: To review our recent experience and the published literature on the topic.. We present a case of invasive sinusitis caused by Fusarium in a patient with refractory chronic lymphocytic leukaemia (CLL) who was treated with IBR and review the 12 published cases of NAIMIs during IBR.. Nearly all cases of NAIMIs in the setting of IBR use were encountered in patients with CLL. Mixed fungal infections, brain involvement and late-onset infections were common.. Although rare, NAIMIs should be considered in patients who receive IBR.

    Topics: Adenine; Aged; Anticarcinogenic Agents; Antifungal Agents; Aspergillosis; Aspergillus; Female; Fungi; Fusariosis; Fusarium; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mucorales; Mycoses; Piperidines

2020

Other Studies

5 other study(ies) available for pci-32765 and Mycoses

ArticleYear
Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection.
    Bone marrow transplantation, 2021, Volume: 56, Issue:8

    Topics: Adenine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mycoses; Piperidines; Pyrazoles; Steroids

2021
Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 12-15, Volume: 71, Issue:12

    Topics: Adenine; B-Lymphocytes; Consensus; Humans; Immunosuppressive Agents; Mycoses; Neoplasms; Piperidines

2020
Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:10

    Topics: Adenine; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Piperidines; Pyrazoles

2020
Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:10

    Topics: Adenine; Humans; Incidence; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Patients; Piperidines; Pyrazoles; Pyrimidines

2020
High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:6

    Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycoses; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence

2019